Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer
PM01183 与拓扑替康治疗铂类耐药/难治性晚期卵巢癌患者的 II 期随机研究
期刊:Annals of Oncology
影响因子:65.4
doi:10.1093/annonc/mdx111
Poveda, A; Del Campo, J M; Ray-Coquard, I; Alexandre, J; Provansal, M; Guerra Alía, E M; Casado, A; Gonzalez-Martin, A; Fernández, C; Rodriguez, I; Soto, A; Kahatt, C; Fernández Teruel, C; Galmarini, C M; Pérez de la Haza, A; Bohan, P; Berton-Rigaud, D